International conference on “Photosynthesis Research for Sustainability-2016”

During June 19–26, 2016, an international conference (http://photosynthesis2016.cellreg.org/) on “Photosynthesis Research for Sustainability-2016” was held in honor of Nathan Nelson and Turhan Nejat Veziro?lu at the Institute of Basic Biological Problems, Russian Academy of Sciences, formerly Institute of Photosynthesis, Academy of Sciences of the USSR, Pushchino, Russia. Further, this conference celebrated the 50th anniversary of the Institute. We provide here a brief introduction and key contributions of the two honored scientists, and then information on the conference, on the speakers, and the program. A special feature of this conference was the awards given to several young investigators, who are recognized in this Report. Several photographs are included to show the excellent ambience at this conference. We invite the readers to the next conference on “Photosynthesis and Hydrogen Energy Research for Sustainability-2017”, which will honor A.S. Raghavendra (of University of Hyderabad), William Cramer (of Purdue University) and Govindjee (of University of Illinois at Urbana-Champaign); it will be held during the Fall of 2017 (from October 30 to November 4), at the University of Hyderabad, Hyderabad, India. See <https://prs.science>.     

Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)

Background

Point of care testing (PoCT) may be a useful adjunct in the management of chronic conditions in general practice (GP). The provision of pathology test results at the time of the consultation could lead to enhanced clinical management, better health outcomes, greater convenience and satisfaction for patients and general practitioners (GPs), and savings in costs and time. It could also result in inappropriate testing, increased consultations and poor health outcomes resulting from inaccurate results. Currently there are very few randomised controlled trials (RCTs) in GP that have investigated these aspects of PoCT.

Design/Methods

The Point of Care Testing in General Practice Trial (PoCT Trial) was an Australian Government funded multi-centre, cluster randomised controlled trial to determine the safety, clinical effectiveness, cost effectiveness and satisfaction of PoCT in a GP setting. The PoCT Trial covered an 18 month period with the intervention consisting of the use of PoCT for seven tests used in the management of patients with diabetes, hyperlipidaemia and patients on anticoagulant therapy. The primary outcome measure was the proportion of patients within target range, a measure of therapeutic control. In addition, the PoCT Trial investigated the safety of PoCT, impact of PoCT on patient compliance to medication, stakeholder satisfaction, cost effectiveness of PoCT versus laboratory testing, and influence of geographic location.

Discussion

The paper provides an overview of the Trial Design, the rationale for the research methodology chosen and how the Trial was implemented in a GP environment. The evaluation protocol and data collection processes took into account the large number of patients, the broad range of practice types distributed over a large geographic area, and the inclusion of pathology test results from multiple pathology laboratories. The evaluation protocol developed reflects the complexity of the Trial setting, the Trial Design and the approach taken within the funding provided. The PoCT Trial is regarded as a pragmatic RCT, evaluating the effectiveness of implementing PoCT in GP and every effort was made to ensure that, in these circumstances, internal and external validity was maintained.

Trial Registration

12612605000272695     

Properties of glucose 6-phosphate and 6-phosphogluconate dehydrogenases of the obligate methylotroph Methylobacillus flagellatum KT

Abstract Extracts from the obligate methylotroph Methylobacillus flagellatum KT and its temperature-sensitive (ts) glucose 6-phosphate dehydrogenase (GPD) mutants were analysed by electrophoresis, isoelectrofocusing and chromatography methods. GPD is present in two forms differing in the isoelectric point (IEP) values, but identical in other properties. Both forms are specific to NAD and NADP, have similar affinity to substrates, exhibit equal levels of inhibition by NAD(P)H and ATP and have the same dependence of activity on temperature. The synthesis of both forms is controlled by one gene. 6-phosphogluconate dehydrogenase (GND) is represented by two proteins with different IEP values. One is specific both to NAD and NADP, is stable and inhibited by NADH and NADPH to a similar extent. The second is specific to NAD only, unstable and inhibited by NADH to a greater extent than by NADPH.     

Phosphorylation on Syk Y342 is important for both ITAM and hemITAM signaling in platelets

Immune cells express receptors bearing an immune tyrosine activation motif (ITAM) containing two YXXL motifs or hemITAMs containing only one YXXL motif. Phosphorylation of the ITAM/hemITAM is mediated by Src family kinases allowing for the binding and activation of spleen tyrosine kinase (Syk). It is believed that Syk must be phosphorylated on tyrosine residues for activation, and Tyr342, а conserved tyrosine in the interdomain B region, has been shown to be critical for regulating Syk in FcεR1-activated mast cells. Syk is a key mediator of signaling pathways downstream of several platelet pathways including the ITAM bearing glycoprotein VI (GPVI)/Fc receptor gamma chain collagen receptor and the hemITAM containing C-type lectin-like receptor-2 (CLEC-2). Since platelet activation is a crucial step in both hemostasis and thrombosis, we evaluated the importance of Syk Y342 in these processes by producing an Syk Y342F knock-in mouse. When using a CLEC-2 antibody as an agonist, reduced aggregation and secretion were observed in Syk Y342F mouse platelets when compared with control mouse platelets. Platelet reactivity was also reduced in response to the GPVI agonist collagen-related peptide. Signaling initiated by either GPVI or CLEC-2 was also greatly inhibited, including Syk Y519/520 phosphorylation. Hemostasis, as measured by tail bleeding time, was not altered in Syk Y342F mice, but thrombus formation in response to FeCl₃ injury was prolonged in Syk Y342F mice. These data demonstrate that phosphorylation of Y342 on Syk following stimulation of either GPVI or CLEC-2 receptors is important for the ability of Syk to transduce a signal.     

Immobilized purple bacteria for light-driven H2 production from starch and potato fermentation effluents

The goal of the study was to show that immobilized purple bacteria could photoproduce H(2) using dark fermentation effluent (FE) as substrate. Simple pretreatment of an inexpensive glass-fiber matrix accelerated the immobilization process. Photobioreactors (PhBR) containing immobilized Rhodobacter sphaeroides GL produced 0.128 L H(2) h(-1) L(-1) of PhBR volume (0.570 L h(-1) L(-1) of matrix) for up to 3 months when continuously fed artificial media with volatile fatty acids (VFAs) or FE from potato and starch fermentations. Hydrogen production was insensitive to NH(4)(+) up to 1 mM and saturated at 8 mM lactate or 1.5% potato FE (diluted in water and supplemented with critical micronutrients). The efficiency of VFA transformation to H(2) was 50-70% of theoretical. At nonlimiting substrate concentrations in artificial media or FE, acetate was utilized before butyrate. High volumetric rates of continuous H(2) photoproduction and stability of the process are advantages of using immobilized cultures. Use of H(2) photoproduction as a polishing step in the treatment of FEs from dark fermentations increased the total amount of H(2) produced from 0.9 to 4.7 mol mol(-1) glucose equivalent in the original potato homogenate.